Anthony Scialli
Gynecology · Washington, DCNPI 1538360714
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $157,828 of the $164,960 with a category attached, or 95.7%. It is spread thinly across 15 manufacturers, the largest accounting for just 16.8%. Reporting peaked in 2022 at $45,906 and has fallen 77.4% since, to $10,379 in 2025.
Across 111 payments — averaging $1486.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$28K
- Seqirus USA Inc$19K
- Xellia Pharmaceuticals$16K
- Sanofi-aventis U.S. LLC$16K
- Sanofi US Services Inc.$15K
- Vertex$14K
- plus $58K from 9 others
Across 70 payments — averaging $1036.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$32K
- Novartis Pharma AG$20K
- Teva Pharmaceuticals USA, Inc.$8K
- Novo Nordisk AS$6K
- Amryt Pharma Holdings Ltd$2K
- Amgen$1K
- plus $3K from 4 others
What the payments were for
- Consulting fees$157,82896%
- Speaking & faculty fees$6,1504%
- Travel & lodging$7110%
- Food & beverage$2720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $27,761 |
| Seqirus USA Inc | 19 | $19,276 |
| Xellia Pharmaceuticals | 4 | $15,951 |
| Sanofi-aventis U.S. LLC | 8 | $15,515 |
| Sanofi US Services Inc. | 2 | $15,003 |
| Vertex | 19 | $13,611 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 4 | $12,750 |
| AbbVie | 14 | $12,138 |
| Novartis Pharma AG | 7 | $8,609 |
| Jazz Pharmaceuticals Inc. | 10 | $7,383 |
| Pfizer | 12 | $7,048 |
| AMAG Pharmaceuticals, Inc. | 1 | $6,563 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $1,375 |
| Janssen Research & Development, LLC | 1 | $1,150 |
| Alnylam Pharmaceuticals Inc. | 1 | $831 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VANCOMYCIN$15,951
- NO PRODUCT DISCUSSED$9,563
- NURTEC ODT$8,423
- MAKENA$6,563
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL)$5,857
- GILENYA$4,641
- Skyrizi$4,063
- FTY720D_GILENYA_NEUROSCIENCE$3,968
- JZP-150$2,700
- AFLURIA QUADRIVALENT$2,613
- LAGEVRIO$2,441
- KESIMPTA$2,321
- MAYZENT$2,321
- Ponvory$1,150
- JZP-250$1,013
- Orilissa$938
- UBRELVY$469
- Rinvoq$469
How this compares
Too few gynecology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Other gynecology in Washington
- Gaby MoawadWashington$1.5M
- James SimonWashington$811K
- Andrew GoldsteinWashington$156K
- Marilyn JeromeWashington$14K
- Erica DavenportWashington$13K
- Julian SafranWashington$6K
- Sharon MaloneWashington$3K
- Alyssa Small LayneWashington$3K
- Bandhana BajajWashington$2K
- George SammanWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.